MDR 4Q FY25 Quarterly Activity Report and 4C
| Stock | Adheris Health Limited (AHE.ASX) |
|---|---|
| Release Time | 31 Jul 2025, 9:22 a.m. |
| Price Sensitive | Yes |
MedAdvisor Reports 4Q FY25 Results and Guidance Update
- 4Q FY25 operating revenue of $18.6 million, down 16.6% on prior corresponding period
- FY25 revenue of $88.0 million, down 27.9% on prior corresponding period
- Successful $7.7 million capital raise to support strategic initiatives
MedAdvisor Limited (ASX: MDR) provided its quarterly activities report and Appendix 4C for the three months ended 30 June 2025 (4Q FY25). The company reported 4Q FY25 operating revenue of $18.6 million, down 16.6% on the prior corresponding period (4Q FY24: $22.3 million). FY25 revenue was $88.0 million, down 27.9% on the prior corresponding period (FY24: $122.1 million). The decline was attributed to continued pharmaceutical customer budgetary pressures and delayed health program launches in the US. 4Q FY25 gross profit was $11.1 million (4Q FY24: $15.5 million), and FY25 gross profit was down 27.9% on the prior corresponding period to $53.5 million (FY23: $74.2 million). The group gross margin for the quarter was 59.7%, compared to 69.5% in 4Q FY24. The company successfully completed a $7.7 million capital raise, including a $5 million placement and a $2.7 million share purchase plan. MedAdvisor also announced the sale of its ANZ business operations to Jonas Software AUS for a headline value of $35 million, plus an estimated $7.35 million earn-out over three years. The company is now debt-free and evaluating strategic options, including the possible sale of its US business.
FY25 revenue guidance revised down to A$88.0 million (previously A$93 - 99 million), gross profit revised down to A$53.8 million (previously A$57 - 60 million), and EBITDA loss revised to A$6.5 -7.3 million (previously A$2.6 - 5.5 million).
Key priorities for FY26 include completing the US commercial team restructuring, launching and scaling the next-generation patient engagement platform, strengthening and expanding the US pharmacy network, and continuing to focus on operational efficiency through Transformation 360. The company remains confident in delivering at least 15% revenue growth in FY26 compared to FY25.